Tong Tong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tong Tong has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Haiwen Ding
Pharmacy, The First Affiliated Hospital of USTC, Hefei, Anhui, China
2 shared publications- Aizong Shen
School of Pharmacy Anhui University of Chinese Medicine 230012 Anhui Hefei China
1 shared publication - Fangqi Gong
Department of Cardiology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
1 shared publication Fangyuan Chen
Pharmacy, The First Affiliated Hospital of USTC, Hefei, Anhui, China
1 shared publication- Haiwen Ding
Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People’s Republic of China
1 shared publication - Jie Li1 shared publication
Latest Publications
- Open Access
- 3 March 2025
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 33 (2) , 171-175
Physical compatibility of ceftazidime-avibactam with selected intravenous antimicrobials in simulated Y-site administration
Objective The primary objective of this study was to evaluate the physical compatibility of ceftazidime-avibactam with selected intravenous antimicrobials during simulated Y-site administration. Methods Ceftazidime-avibactam (25 mg/mL) was mixed with select intravenous antimicrobials (tigecycline, metronidazole, meropenem, imipenem and cilastatin, fosfomycin, aztreonam and vancomycin) at an equal volume and evaluated using simulated Y-sites. Each admixture was evaluated immediately (0 hour) and after 1, 2, and 4 hours at room temperature (approximately 22°C) for visual characteristics, Tyndall beam, turbidity, pH, spectroscopic absorption of 550 nm and particle counts. If an admixture failed any one of these six assessments, it was considered incompatible. Results No evidence of incompatibility was observed between the combinations of ceftazidime-avibactam and the seven intravenous antimicrobials in simulated Y-site experiments. Conclusion Ceftazidime-avibactam was physically compatible with the selected intravenous antimicrobials (tigecycline, metronidazole, meropenem, imipenem and cilastatin, fosfomycin, aztreonam and vancomycin) in simulated Y-site administration.
- 3 March 2025
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 33 (2) , 171-175
Open AccessPhysical compatibility of ceftazidime-avibactam with selected intravenous antimicrobials in simulated Y-site administration
Objective The primary objective of this study was to evaluate the physical compatibility of ceftazidime-avibactam with selected intravenous antimicrobials during simulated Y-site administration. Methods Ceftazidime-avibactam (25 mg/mL) was mixed with select intravenous antimicrobials (tigecycline, metronidazole, meropenem, imipenem and cilastatin, fosfomycin, aztreonam and vancomycin) at an equal volume and evaluated using simulated Y-sites. Each admixture was evaluated immediately (0 hour) and after 1, 2, and 4 hours at room temperature (approximately 22°C) for visual characteristics, Tyndall beam, turbidity, pH, spectroscopic absorption of 550 nm and particle counts. If an admixture failed any one of these six assessments, it was considered incompatible. Results No evidence of incompatibility was observed between the combinations of ceftazidime-avibactam and the seven intravenous antimicrobials in simulated Y-site experiments. Conclusion Ceftazidime-avibactam was physically compatible with the selected intravenous antimicrobials (tigecycline, metronidazole, meropenem, imipenem and cilastatin, fosfomycin, aztreonam and vancomycin) in simulated Y-site administration.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Concurrent Intravenous Drug Administration to the Critically Ill: Compatibility of Ginkgo Biloba Extract With Frequently Used Drugs in the Neurological Intensive Care Unit
Objective: Ginkgo biloba extract (EGB), a traditional Chinese medicine extracted from the Ginkgophyta, was used to regulate various neurological disorders (NDs). Limited compatibility data exist on EGB after marketing with other drugs administered simultaneously through the Y‐site. This study aimed to determine the compatibility of EGB during simulated Y‐site administration with 35 continuous infusion drugs that are commonly administered in the neurological intensive care units ( NICU s). Methods: The compatibility of EGB with these drugs was determined using a well‐established experimental model to simulate Y‐site administration. EGB (0.35 mg/mL) was mixed in a volume ratio of 1:1 with the secondary drug solution to simulate Y‐site coadministration procedures in NICUs. All other drugs were prepared at maximum concentrations commonly administered in the clinical setting. Compatibility was assessed by visual inspection (observations of haziness, color change, or precipitate formation), the Tyndall effect, chromaticity, pH, turbidity, insoluble particles, and UV absorption at 0, 1, 2, and 4 h postmixing. Results: This study has identified 25 (71%) combinations that are compatible and 10 combinations that are incompatible within four hours. Visual changes occurred with EGB + acyclovir and EGB + ganciclovir. The turbidity of the mixed solution of EGB + calcium gluconate exceeds the specification. Binary combinations of EGB + aceglutamide, EGB + aescin sodium, EGB + amiodarone hydrochloride, EGB + fosfomycin, EGB + ganciclovir, EGB + meropenem, EGB + omeprazole, and EGB + vinpocetine had particles that grew over the limitation of the Chinese Pharmacopoeia specification. Both admixtures of EGB + acyclovir and EGB + amiodarone hydrochloride absorption at 420 nm and 550 nm exceeded the prescribed limits. Conclusion: It is strongly advised against combining EGB 0.35 mg/mL with acyclovir, aceglutamide, aescin sodium, amiodarone hydrochloride, calcium gluconate, fosfomycin sodium, ganciclovir, meropenem, or omeprazole, as well as vinpocetine. If coadministration is inevitable, a larger volume of saline (NS) or dextrose 5% in water (D5W) should be used to flush the port catheter before and after the EGB infusion to clean the lumen of the port catheter.
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Open AccessConcurrent Intravenous Drug Administration to the Critically Ill: Compatibility of Ginkgo Biloba Extract With Frequently Used Drugs in the Neurological Intensive Care Unit
Objective: Ginkgo biloba extract (EGB), a traditional Chinese medicine extracted from the Ginkgophyta, was used to regulate various neurological disorders (NDs). Limited compatibility data exist on EGB after marketing with other drugs administered simultaneously through the Y‐site. This study aimed to determine the compatibility of EGB during simulated Y‐site administration with 35 continuous infusion drugs that are commonly administered in the neurological intensive care units ( NICU s). Methods: The compatibility of EGB with these drugs was determined using a well‐established experimental model to simulate Y‐site administration. EGB (0.35 mg/mL) was mixed in a volume ratio of 1:1 with the secondary drug solution to simulate Y‐site coadministration procedures in NICUs. All other drugs were prepared at maximum concentrations commonly administered in the clinical setting. Compatibility was assessed by visual inspection (observations of haziness, color change, or precipitate formation), the Tyndall effect, chromaticity, pH, turbidity, insoluble particles, and UV absorption at 0, 1, 2, and 4 h postmixing. Results: This study has identified 25 (71%) combinations that are compatible and 10 combinations that are incompatible within four hours. Visual changes occurred with EGB + acyclovir and EGB + ganciclovir. The turbidity of the mixed solution of EGB + calcium gluconate exceeds the specification. Binary combinations of EGB + aceglutamide, EGB + aescin sodium, EGB + amiodarone hydrochloride, EGB + fosfomycin, EGB + ganciclovir, EGB + meropenem, EGB + omeprazole, and EGB + vinpocetine had particles that grew over the limitation of the Chinese Pharmacopoeia specification. Both admixtures of EGB + acyclovir and EGB + amiodarone hydrochloride absorption at 420 nm and 550 nm exceeded the prescribed limits. Conclusion: It is strongly advised against combining EGB 0.35 mg/mL with acyclovir, aceglutamide, aescin sodium, amiodarone hydrochloride, calcium gluconate, fosfomycin sodium, ganciclovir, meropenem, or omeprazole, as well as vinpocetine. If coadministration is inevitable, a larger volume of saline (NS) or dextrose 5% in water (D5W) should be used to flush the port catheter before and after the EGB infusion to clean the lumen of the port catheter.
- Open Access
- 22 March 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (3) , e0299694
Physical compatibility of Xuebijing injection with 53 intravenous drugs during simulated Y-site administration
Objective: Xuebijing injection (XBJ) is a commonly used herbal medicine injection in China. However, the physical compatibility of XBJ with other intravenous drugs remains unclear. The purpose of this research is to evaluate physical compatibility of Xuebijing injection (XBJ) with 53 intravenous drugs (including 31 Chinese medicine injections and 22 chemicals) during simulated Y-site administration.Methods: Y-site administration was simulated in vitro by admixing 0.33 ml/ml XBJ with an equal volume of other diluted 53 intravenous drugs, respectively. Physical compatibility including visual inspection, Tyndall beam, particle limits, turbidity, pH, chromacity value, spectroscopic absorption of 550 nm and 420 nm (A550 nmand A420 nm) were observed and assessed at 0, 1, 2, and 4 h. Physical compatibility was defined as all solutions with no color changes, no gas evolution, particulate formation and no Tyndall beam within 4 hours, turbidity changes 420 nm550 nm550 nmwere proved to be valid and robust for the quality control of infusion and compatibility of Chinese herbal injection.
- 22 March 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (3) , e0299694
Open AccessPhysical compatibility of Xuebijing injection with 53 intravenous drugs during simulated Y-site administration
Objective: Xuebijing injection (XBJ) is a commonly used herbal medicine injection in China. However, the physical compatibility of XBJ with other intravenous drugs remains unclear. The purpose of this research is to evaluate physical compatibility of Xuebijing injection (XBJ) with 53 intravenous drugs (including 31 Chinese medicine injections and 22 chemicals) during simulated Y-site administration.Methods: Y-site administration was simulated in vitro by admixing 0.33 ml/ml XBJ with an equal volume of other diluted 53 intravenous drugs, respectively. Physical compatibility including visual inspection, Tyndall beam, particle limits, turbidity, pH, chromacity value, spectroscopic absorption of 550 nm and 420 nm (A550 nmand A420 nm) were observed and assessed at 0, 1, 2, and 4 h. Physical compatibility was defined as all solutions with no color changes, no gas evolution, particulate formation and no Tyndall beam within 4 hours, turbidity changes 420 nm550 nm550 nmwere proved to be valid and robust for the quality control of infusion and compatibility of Chinese herbal injection.
- 21 March 2024
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 20 (4) , 325-339
Treatment of multisystem inflammatory syndrome in children
Background Multisystem inflammatory syndrome in children (MIS-C), a relatively uncommon but severe pediatric complication, is associated with coronavirus disease 2019 (COVID-19). A variety of treatment approaches, including intravenous immunoglobulins (IVIGs), glucocorticoids (GCs) and biologic agents, such as anakinra and infliximab, have been described for the management of COVID-19-related MIS-C. Anticoagulant therapy is also important. However, a well-developed treatment system has not been established, and many issues remain controversial. Several recently published articles related to the treatment of MIS-C have been released. Hence, in this review, we identified relevant articles published recently and summarized the treatment of MIS-C more comprehensively and systematically. Data sources We reviewed the literature on the treatment of MIS-C through 20 September 2023. The PubMed/Medline, Web of Science, EMBASE, and Cochrane Library databases were searched with the combination of the terms “multisystem inflammatory syndrome”, “MIS-C”, “PIMS-TS”, “therapy”, “treatment”, “drug”, “IVIG”, “GCs”, “intravenous immunoglobulin”, “corticosteroids”, “biological agent”, and “aspirin”. Results The severity of MIS-C varies, and different treatment schemes should be used according to the specific condition. Ongoing research and data collection are vital to better understand the pathophysiology and optimal management of MIS-C. Conclusions MIS-C is a disease involving multiple systems and has great heterogeneity. With the accumulation of additional experience, we have garnered fresh insights into its treatment strategies. However, there remains a critical need for greater standardization in treatment protocols, alongside the pressing necessity for more robust and meticulously conducted studies to deepen our understanding of these protocols. Video abstract Supplementary file1 (MP4 208044 kb)
- 21 March 2024
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 20 (4) , 325-339
Treatment of multisystem inflammatory syndrome in children
Background Multisystem inflammatory syndrome in children (MIS-C), a relatively uncommon but severe pediatric complication, is associated with coronavirus disease 2019 (COVID-19). A variety of treatment approaches, including intravenous immunoglobulins (IVIGs), glucocorticoids (GCs) and biologic agents, such as anakinra and infliximab, have been described for the management of COVID-19-related MIS-C. Anticoagulant therapy is also important. However, a well-developed treatment system has not been established, and many issues remain controversial. Several recently published articles related to the treatment of MIS-C have been released. Hence, in this review, we identified relevant articles published recently and summarized the treatment of MIS-C more comprehensively and systematically. Data sources We reviewed the literature on the treatment of MIS-C through 20 September 2023. The PubMed/Medline, Web of Science, EMBASE, and Cochrane Library databases were searched with the combination of the terms “multisystem inflammatory syndrome”, “MIS-C”, “PIMS-TS”, “therapy”, “treatment”, “drug”, “IVIG”, “GCs”, “intravenous immunoglobulin”, “corticosteroids”, “biological agent”, and “aspirin”. Results The severity of MIS-C varies, and different treatment schemes should be used according to the specific condition. Ongoing research and data collection are vital to better understand the pathophysiology and optimal management of MIS-C. Conclusions MIS-C is a disease involving multiple systems and has great heterogeneity. With the accumulation of additional experience, we have garnered fresh insights into its treatment strategies. However, there remains a critical need for greater standardization in treatment protocols, alongside the pressing necessity for more robust and meticulously conducted studies to deepen our understanding of these protocols. Video abstract Supplementary file1 (MP4 208044 kb)
- Open Access
- 24 May 2020
- Published by Springer Nature in Chinese Medicine
- Vol. 15 (1) , 1-6
The potential insights of Traditional Chinese Medicine on treatment of COVID-19
Corona Virus Disease 2019 (COVID-19) broke out in 2019 and spread rapidly around the world. There is still no specific antiviral therapy to the current pandemic. In China, historical records show that Traditional Chinese Medicine (TCM) is effective in prevention and enhancing the resistance to pandemic with unique insights. To fight with COVID-19, National Health and Commission of PRC has recommended some TCM in the guideline, such as HuoxiangZhengqi, LianhuaQingwen ShufengJiedu and XueBijing, and actually displayed a remarkable effect in clinical treatment strategic for COVID-19. We review studies to provide an in-depth understanding into the effect of TCM, and also introduce the possible mechanism involved in COVID-19 treatment.
- 24 May 2020
- Published by Springer Nature in Chinese Medicine
- Vol. 15 (1) , 1-6
Open AccessThe potential insights of Traditional Chinese Medicine on treatment of COVID-19
Corona Virus Disease 2019 (COVID-19) broke out in 2019 and spread rapidly around the world. There is still no specific antiviral therapy to the current pandemic. In China, historical records show that Traditional Chinese Medicine (TCM) is effective in prevention and enhancing the resistance to pandemic with unique insights. To fight with COVID-19, National Health and Commission of PRC has recommended some TCM in the guideline, such as HuoxiangZhengqi, LianhuaQingwen ShufengJiedu and XueBijing, and actually displayed a remarkable effect in clinical treatment strategic for COVID-19. We review studies to provide an in-depth understanding into the effect of TCM, and also introduce the possible mechanism involved in COVID-19 treatment.